您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > Gatifloxacin
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Gatifloxacin
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Gatifloxacin图片
CAS NO:112811-59-3
包装与价格:
包装价格(元)
10mM (in 1mL DMSO)电议
5mg电议
100mg电议

产品介绍
Gatifloxacin (AM-1155; BMS-206584; PD135432) 是一种具有广谱抗菌活性的强效氟喹诺酮类抗生素。
Cas No.112811-59-3
别名加替沙星; AM-1155; BMS-206584; PD135432
化学名1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid
Canonical SMILESCC1CN(CCN1)C2=C(C=C3C(=C2OC)N(C=C(C3=O)C(=O)O)C4CC4)F
分子式C19H22FN3O4
分子量375.39
溶解度≥ 3.75mg/mL in DMSO with gentle warming
储存条件Store at -20℃, stored under nitrogen
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, it inhibits the bacterial enzymes DNA gyrase and topoisomerase IV.Target: AntibacterialGatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial enzymes DNA gyrase and topoisomerase IV. Gatifloxacin had activity equal to that of tosufloxacin and activity more potent than those of norfloxacin, ofloxacin, ciprofloxacin, and sparfloxacin against the second-step mutants (grlA gyrA; gatifloxacin MIC range, 1.56 to 3.13 microg/ml) and had the most potent activity against the third-step mutants (grlA gyrA grlA; gatifloxacin MIC range, 1.56 to 6.25 microg/ml), suggesting that gatifloxacin possesses the most potent inhibitory activity against singly mutated topo IV and singly mutated DNA gyrase among the quinolones tested [1].Ophthalmic gatifloxacin 0.3% is at least as effective as ciprofloxacin at healing corneal ulcers infected with Pseudomonas aeruginosa when gatifloxacin is administered less frequently than ciprofloxacin. Trends favored gatifloxacin in fluorescein retention scores [2].Clinical indications: Bacterial infection FDA Approved Date: Toxicity: Hepatotoxicity; Acute pancreatitis [3]; Torsades de pointes [4]

References:
[1]. Fukuda, H., S. Hori, and K. Hiramatsu, Antibacterial activity of gatifloxacin (AM-1155, CG5501, BMS-206584), a newly developed fluoroquinolone, against sequentially acquired quinolone-resistant mutants and the norA transformant of Staphylococcus aureus. Antimicrob Agents Chemother, 1998. 42(8): p. 1917-22.
[2]. Jensen, H., et al., Comparison of ophthalmic gatifloxacin 0.3% and ciprofloxacin 0.3% in healing of corneal ulcers associated with Pseudomonas aeruginosa-induced ulcerative keratitis in rabbits. J Ocul Pharmacol Ther, 2005. 21(1): p. 36-43.
[3]. Cheung, O., et al., Gatifloxacin-induced hepatotoxicity and acute pancreatitis. Ann Intern Med, 2004. 140(1): p. 73-4.
[4]. Fteha, A., et al., Gatifloxacin induced torsades de pointes. Pacing Clin Electrophysiol, 2004. 27(10): p. 1449-50.